Potential Cost‐Saving Model Utilizing Mark Cuban Cost Plus Drug Company for Purchasing Common Otolaryngology Medications
Otolaryngology–Head and Neck Surgery · 2025
DOI: 10.1002/ohn.1058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2025. Verfasst von Zachary Buxo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Cost Savings, Otolaryngology, Drug Industry, Drug Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
The persistent challenge of high pharmaceutical prices has led to the emergence of vertically integrated direct‐to‐consumer distributors like Mark Cuban Cost Plus Drug Company (MCCPDC). This study aims to evaluate a cost‐saving alternative method for medication sourcing. The most frequently prescribed medications by otolaryngologists were identified through analysis of Medicare Part D data, utilizing prescriber type as a filter. Medications were assessed for availability on the MCCPDC website and drug form consistency. Cost analysis was conducted comparing current pharmaceutical spending against MCCPDC pricing. Potential otolaryngology‐driven savings were estimated at $55.6 million and $1 billion if in effect across all specialties. Our findings suggest considerable potential savings for Medicare by purchasing generic medications at MCCPDC prices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA.
ORCID-Profile: Zachary Buxo
Zitieren
APA
Buxo, Z., & D Cramer, J. (2025). Potential Cost‐Saving Model Utilizing Mark Cuban Cost Plus Drug Company for Purchasing Common Otolaryngology Medications. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1058
Vancouver
Buxo Z, D Cramer J. Potential Cost‐Saving Model Utilizing Mark Cuban Cost Plus Drug Company for Purchasing Common Otolaryngology Medications. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1058
BibTeX
@article{Buxo2025,
author = {Buxo, Zachary and D Cramer, John},
title = {Potential Cost‐Saving Model Utilizing Mark Cuban Cost Plus Drug Company for Purchasing Common Otolaryngology Medications},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2025},
doi = {10.1002/ohn.1058}
}
EUVIMED